Log in to search using one of your social media accounts:

 

HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer

Condition:   Prostate Cancer Intervention:   Radiation: HDR brachytherapy as monotherapy Sponsor:   CR-CSSS Champlain-Charles-Le Moyne Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

CONCLUSIONS: Low-dose brachytherapy offers good short- to intermediate-term cancer control in selected men with localized PCa. Further studies are needed for safety analyses and for comparison with other treatment modalities. PMID: 29463165 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Tags: Scand J Urol Source Type: research
We report late toxicity of a prospective Phase I/II trial employing an MRI assisted focal boost integrated with HDR brachytherapy alone for treatment of low and intermediate risk prostate cancer.
Source: Journal of Medical Imaging and Radiation Sciences - Category: Radiology Authors: Tags: 2018 RTi3 Abstracts Source Type: research
Authors: Skowronek J Abstract Cancer incidence and mortality depend on a number of factors, including age, socio-economic status and geographical location, and its prevalence is growing around the world. Most of cancer treatments include external beam radiotherapy or brachytherapy. Brachytherapy, a type of radiotherapy with energy from radionuclides inserted directly into the tumor, is increasingly used in cancer treatment. For cervical and skin cancers, it has become a standard therapy for more than 100 years as well as an important part of the treatment guidelines for other malignancies, including head and neck, ...
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
Conclusions: Post-implant D90 of PSQ is significantly associated with BFFS for localized prostate cancer not only at 1 month, but also at 24 hours. D90 of PSQ at 1 month is also a significant factor for rectal hemorrhage. PMID: 29441093 [PubMed]
Source: Journal of Contemporary Brachytherapy - Category: Cancer & Oncology Tags: J Contemp Brachytherapy Source Type: research
ObjectiveTo evaluate the cancer control outcomes and long‐term treatment‐related morbidity of brachytherapy as well as combination brachytherapy and external beam radiation therapy (EBRT) in patients with intermediate‐risk prostate cancer. Materials and MethodsA retrospective review was conducted in a prospectively collected database of patients with intermediate‐risk prostate cancer who were treated either with brachytherapy or brachytherapy and EBRT, with or without androgen deprivation therapy (ADT), in the period 1990–2014. Urinary and erectile dysfunction symptoms were measured using the International Pr...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Conclusion The evidence for SBRT in HR patients in this review is based on observational studies with relatively few patients and short follow-up (level III evidence). Based on these data and the principles surrounding treatment, SBRT boost should ideally be validated in clinical trials. SBRT monotherapy should be used cautiously in highly selected HR patients outside of a clinical trial. Summary Stereotactic body radiation therapy (SBRT) is increasingly being used for the management of clinically localized prostate cancer. This trend, combined with the decline in the use of brachytherapy, has pushed issues and questions r...
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Condition:   Prostate Cancer Interventions:   Radiation: Low dose rate prostate brachytherapy;   Radiation: High dose rate prostate brachytherapy Sponsors:   British Columbia Cancer Agency;   BC Cancer Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Interventions:   Radiation: Low dose rate prostate brachytherapy;   Radiation: High dose rate prostate brachytherapy Sponsors:   British Columbia Cancer Agency;   BC Cancer Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Interventions:   Radiation: Low dose rate prostate brachytherapy;   Radiation: High dose rate prostate brachytherapy Sponsors:   British Columbia Cancer Agency;   BC Cancer Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Prostate Cancer Interventions:   Radiation: Low dose rate prostate brachytherapy;   Radiation: High dose rate prostate brachytherapy Sponsors:   British Columbia Cancer Agency;   BC Cancer Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Brachytherapy | Cancer | Cancer & Oncology | Prostate Cancer